Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (HKG:9989)

Market Cap	15.36B -0.7%
Revenue (ttm)	6.16B +2.1%
Net Income	432.46M -41.3%
EPS	0.29 -41.3%
Shares Out	n/a
PE Ratio	35.51
Forward PE	n/a
Dividend	0.17 (4.00%)
Ex-Dividend Date	May 27, 2026

Volume	646,000
Open	4.100
Previous Close	4.130
Day's Range	4.090 - 4.190
52-Week Range	4.010 - 7.260
Beta	0.36
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About HKG:9989

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs. It also provides molecule biologics CDMO services, which include...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 2,150
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9989

Financial Performance

In 2025, HKG:9989's revenue was 5.48 billion, an increase of 3.75% compared to the previous year's 5.28 billion. Earnings were 349.49 million, a decrease of -45.96%.

Financial numbers in CNY